Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Deep Dives
Consulting
Archive
About
Latest
Top
Discussions
Merck's $6.7B Bet and the First Drug to Reach the Brain in Hunter Syndrome – This Week in Biotech #93
Plus Sarepta's first human proof for gene-silencing in muscular dystrophy, a CDC leadership vacuum, and what it all means for biotech (March 20-26…
Mar 27
•
Katerina Roznik
12
1
TrumpRx Price Claims Get Fact-Checked, RFK Jr.’s Vaccine Overhaul Paused, Lilly’s Retatrutide Hits Phase 3 – This Week in Biotech #92
A judge freezes ACIP changes, J&J wins a plaque psoriasis pill approval, and Lilly raises the bar again in obesity and diabetes (Mar 13-19, 2026).
Mar 20
•
Katerina Roznik
7
1
This Week in Biotech: Brief Update
On pause for two weeks, back March 20.
Mar 6
•
Katerina Roznik
8
1
February 2026
Novo's CagriSema Loses to Zepbound, Grail Stumbles, FDA Hardens Its Stance – This Week in Biotech #91
CagriSema lost the obesity head-to-head with Lilly's Zepbound, Galleri misses its primary endpoint, and the FDA signals tougher tolerance for invasive…
Feb 27
•
Katerina Roznik
4
FDA Shifts to One Pivotal Trial and Moderna Flu Shot Back Under FDA Review – This Week in Biotech #90
Plus Compass psilocybin Phase 3 win and China’s biotech licensing surge (Feb 13-19, 2026).
Feb 20
•
Katerina Roznik
6
1
Moderna Flu Filing Rejected, Sanofi Replaces CEO, AbbVie Sues Over Botox Medicare Pricing – This Week in Biotech #89
CBER’s Refusal to File jolts FDA predictability, Sanofi swaps CEOs, AbbVie sues over Botox Medicare pricing, and BridgeBio’s Phase 3 win contrasts with…
Feb 13
•
Katerina Roznik
9
Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88
Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026).
Feb 6
•
Katerina Roznik
4
January 2026
Regenxbio FDA Hold, Sanofi Vaccine Demand Softness, and CMS Negotiation Expansion – This Week in Biotech #87
FDA pauses two AAV programs, Sanofi reports US vaccine uptake slipping, and CMS widens negotiations to more blockbuster drugs (Jan 23-29, 2026).
Jan 30
•
Katerina Roznik
8
1
Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up – This Week in Biotech #86
KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners Janux, Corcept's overall survival win, and Corvus posts Phase 1 eczema…
Jan 23
•
Katerina Roznik
3
Drug Pricing Returns, AI Labs Scale Up, Gene Therapy Pushes Mainstream – This Week in Biotech #85
(Jan 9-15, 2026)
Jan 16
•
Katerina Roznik
13
1
CDC Vaccine Schedule Shifts, Practice-Changing Phase 3 Wins, and Deal Heat – This Week in Biotech #84
Revolution takeover rumors, Amgen and Lilly pay early for platforms, plus phase 3 wins in gastroesophageal cancer, psoriasis, and hepatitis B amid a CDC…
Jan 9
•
Katerina Roznik
8
Biotech Heads Into 2026: Obesity, Vaccines, Pricing & Risk — This Week in Biotech #83
A year end / new-year update on what actually moved during the holiday stretch (Dec 19, 2025 – Jan 1, 2026).
Jan 2
•
Katerina Roznik
9
1
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
